nodes	percent_of_prediction	percent_of_DWPC	metapath
Betamethasone—PTGS2—Etoposide—sarcoma	0.122	0.217	CbGbCtD
Betamethasone—CYP3A4—Thiotepa—sarcoma	0.0891	0.158	CbGbCtD
Betamethasone—ABCB1—Dactinomycin—sarcoma	0.0714	0.127	CbGbCtD
Betamethasone—ABCB1—Mitoxantrone—sarcoma	0.0639	0.113	CbGbCtD
Betamethasone—ABCB1—Vincristine—sarcoma	0.044	0.078	CbGbCtD
Betamethasone—ABCB1—Etoposide—sarcoma	0.0403	0.0715	CbGbCtD
Betamethasone—CYP3A4—Mitoxantrone—sarcoma	0.0383	0.0679	CbGbCtD
Betamethasone—ABCB1—Doxorubicin—sarcoma	0.0275	0.0488	CbGbCtD
Betamethasone—CYP3A4—Vincristine—sarcoma	0.0264	0.0468	CbGbCtD
Betamethasone—CYP3A4—Etoposide—sarcoma	0.0241	0.0428	CbGbCtD
Betamethasone—CYP3A4—Doxorubicin—sarcoma	0.0165	0.0292	CbGbCtD
Betamethasone—PTGS2—periosteum—sarcoma	0.00592	0.0515	CbGeAlD
Betamethasone—PTGS2—leg—sarcoma	0.00472	0.041	CbGeAlD
Betamethasone—PLA2G1B—hematopoietic system—sarcoma	0.00466	0.0405	CbGeAlD
Betamethasone—PLA2G1B—connective tissue—sarcoma	0.00449	0.039	CbGeAlD
Betamethasone—PTGS2—hindlimb—sarcoma	0.00421	0.0366	CbGeAlD
Betamethasone—PTGS2—cartilage tissue—sarcoma	0.00415	0.0361	CbGeAlD
Betamethasone—PTGS2—appendage—sarcoma	0.00361	0.0314	CbGeAlD
Betamethasone—PGR—mammary gland—sarcoma	0.00352	0.0306	CbGeAlD
Betamethasone—NR3C2—myometrium—sarcoma	0.00269	0.0234	CbGeAlD
Betamethasone—PLA2G1B—testis—sarcoma	0.00255	0.0222	CbGeAlD
Betamethasone—PGR—myometrium—sarcoma	0.0025	0.0217	CbGeAlD
Betamethasone—NR3C2—seminal vesicle—sarcoma	0.00243	0.0211	CbGeAlD
Betamethasone—NR3C2—hematopoietic system—sarcoma	0.00231	0.0201	CbGeAlD
Betamethasone—NR3C2—connective tissue—sarcoma	0.00222	0.0193	CbGeAlD
Betamethasone—PTGS2—endothelium—sarcoma	0.00218	0.019	CbGeAlD
Betamethasone—PGR—hematopoietic system—sarcoma	0.00215	0.0187	CbGeAlD
Betamethasone—PGR—connective tissue—sarcoma	0.00207	0.018	CbGeAlD
Betamethasone—NR3C2—smooth muscle tissue—sarcoma	0.00203	0.0177	CbGeAlD
Betamethasone—CYP19A1—hematopoietic system—sarcoma	0.00193	0.0168	CbGeAlD
Betamethasone—PGR—smooth muscle tissue—sarcoma	0.00189	0.0164	CbGeAlD
Betamethasone—CYP19A1—connective tissue—sarcoma	0.00186	0.0162	CbGeAlD
Betamethasone—NR3C2—cardiac atrium—sarcoma	0.00175	0.0152	CbGeAlD
Betamethasone—NR3C2—uterus—sarcoma	0.00174	0.0152	CbGeAlD
Betamethasone—PGR—Ovarian Infertility Genes—GJA4—sarcoma	0.00174	0.07	CbGpPWpGaD
Betamethasone—PGR—uterus—sarcoma	0.00162	0.0141	CbGeAlD
Betamethasone—NR3C2—tendon—sarcoma	0.00153	0.0133	CbGeAlD
Betamethasone—PGR—lymphoid tissue—sarcoma	0.00151	0.0131	CbGeAlD
Betamethasone—CYP19A1—uterus—sarcoma	0.00146	0.0127	CbGeAlD
Betamethasone—NR3C1—myometrium—sarcoma	0.00144	0.0125	CbGeAlD
Betamethasone—NR3C1—embryo—sarcoma	0.00139	0.0121	CbGeAlD
Betamethasone—NR3C1—seminal vesicle—sarcoma	0.0013	0.0113	CbGeAlD
Betamethasone—NR3C2—testis—sarcoma	0.00126	0.011	CbGeAlD
Betamethasone—PTGS2—myometrium—sarcoma	0.00125	0.0109	CbGeAlD
Betamethasone—NR3C1—hematopoietic system—sarcoma	0.00124	0.0108	CbGeAlD
Betamethasone—PTGS2—embryo—sarcoma	0.0012	0.0104	CbGeAlD
Betamethasone—NR3C2—liver—sarcoma	0.0012	0.0104	CbGeAlD
Betamethasone—NR3C1—connective tissue—sarcoma	0.00119	0.0104	CbGeAlD
Betamethasone—PGR—testis—sarcoma	0.00118	0.0102	CbGeAlD
Betamethasone—CYP19A1—Ovarian Infertility Genes—GJA4—sarcoma	0.00114	0.0459	CbGpPWpGaD
Betamethasone—PTGS2—seminal vesicle—sarcoma	0.00113	0.00981	CbGeAlD
Betamethasone—NR3C1—smooth muscle tissue—sarcoma	0.00109	0.00948	CbGeAlD
Betamethasone—NR3C1—skin of body—sarcoma	0.00108	0.00936	CbGeAlD
Betamethasone—PTGS2—hematopoietic system—sarcoma	0.00107	0.00932	CbGeAlD
Betamethasone—CYP19A1—testis—sarcoma	0.00106	0.0092	CbGeAlD
Betamethasone—PTGS2—connective tissue—sarcoma	0.00103	0.00897	CbGeAlD
Betamethasone—CYP19A1—liver—sarcoma	0.001	0.0087	CbGeAlD
Betamethasone—PLA2G1B—Fc-epsilon receptor I signaling in mast cells—PLCG1—sarcoma	0.000957	0.0385	CbGpPWpGaD
Betamethasone—PTGS2—smooth muscle tissue—sarcoma	0.000944	0.00821	CbGeAlD
Betamethasone—NR3C1—cardiac atrium—sarcoma	0.00094	0.00818	CbGeAlD
Betamethasone—CYP3A4—hematopoietic system—sarcoma	0.000936	0.00814	CbGeAlD
Betamethasone—NR3C1—uterus—sarcoma	0.000935	0.00813	CbGeAlD
Betamethasone—PTGS2—skin of body—sarcoma	0.000931	0.0081	CbGeAlD
Betamethasone—NR3C2—lymph node—sarcoma	0.000917	0.00797	CbGeAlD
Betamethasone—NR3C1—lymphoid tissue—sarcoma	0.000871	0.00758	CbGeAlD
Betamethasone—PGR—Validated nuclear estrogen receptor alpha network—COL18A1—sarcoma	0.000862	0.0347	CbGpPWpGaD
Betamethasone—PGR—lymph node—sarcoma	0.000852	0.00741	CbGeAlD
Betamethasone—NR3C1—tendon—sarcoma	0.000819	0.00713	CbGeAlD
Betamethasone—PTGS2—uterus—sarcoma	0.000809	0.00704	CbGeAlD
Betamethasone—NR3C1—bone marrow—sarcoma	0.000794	0.0069	CbGeAlD
Betamethasone—ABCB1—myometrium—sarcoma	0.000772	0.00671	CbGeAlD
Betamethasone—CYP19A1—lymph node—sarcoma	0.000767	0.00667	CbGeAlD
Betamethasone—PTGS2—lymphoid tissue—sarcoma	0.000754	0.00656	CbGeAlD
Betamethasone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—ATF1—sarcoma	0.000744	0.03	CbGpPWpGaD
Betamethasone—ABCB1—embryo—sarcoma	0.000742	0.00646	CbGeAlD
Betamethasone—PTGS2—tendon—sarcoma	0.000709	0.00617	CbGeAlD
Betamethasone—ABCB1—seminal vesicle—sarcoma	0.000697	0.00607	CbGeAlD
Betamethasone—PTGS2—bone marrow—sarcoma	0.000687	0.00597	CbGeAlD
Betamethasone—NR3C1—testis—sarcoma	0.000678	0.0059	CbGeAlD
Betamethasone—ABCB1—hematopoietic system—sarcoma	0.000663	0.00576	CbGeAlD
Betamethasone—NR3C1—liver—sarcoma	0.000641	0.00558	CbGeAlD
Betamethasone—PTGS2—S1P1 pathway—PLCG1—sarcoma	0.000594	0.0239	CbGpPWpGaD
Betamethasone—PTGS2—liver—sarcoma	0.000555	0.00483	CbGeAlD
Betamethasone—ABCB1—uterus—sarcoma	0.000501	0.00435	CbGeAlD
Betamethasone—NR3C1—Transcription factor regulation in adipogenesis—FOXO1—sarcoma	0.000494	0.0199	CbGpPWpGaD
Betamethasone—NR3C1—lymph node—sarcoma	0.000492	0.00428	CbGeAlD
Betamethasone—CYP3A4—liver—sarcoma	0.000485	0.00422	CbGeAlD
Betamethasone—PTGS2—Signaling mediated by p38-alpha and p38-beta—MITF—sarcoma	0.000479	0.0193	CbGpPWpGaD
Betamethasone—CYP19A1—FSH signaling pathway—FOXO1—sarcoma	0.000476	0.0192	CbGpPWpGaD
Betamethasone—ABCB1—lymphoid tissue—sarcoma	0.000467	0.00406	CbGeAlD
Betamethasone—Thrombocytopenia—Vincristine—sarcoma	0.000463	0.00156	CcSEcCtD
Betamethasone—Anaphylactic shock—Mitoxantrone—sarcoma	0.000461	0.00155	CcSEcCtD
Betamethasone—Oedema—Mitoxantrone—sarcoma	0.000461	0.00155	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Thiotepa—sarcoma	0.000461	0.00155	CcSEcCtD
Betamethasone—Decreased appetite—Dactinomycin—sarcoma	0.00046	0.00155	CcSEcCtD
Betamethasone—Fatigue—Thiotepa—sarcoma	0.00046	0.00155	CcSEcCtD
Betamethasone—Infection—Mitoxantrone—sarcoma	0.000458	0.00154	CcSEcCtD
Betamethasone—Hyperhidrosis—Vincristine—sarcoma	0.000457	0.00154	CcSEcCtD
Betamethasone—Dermatitis bullous—Epirubicin—sarcoma	0.000457	0.00154	CcSEcCtD
Betamethasone—Fatigue—Dactinomycin—sarcoma	0.000457	0.00154	CcSEcCtD
Betamethasone—Pain—Thiotepa—sarcoma	0.000456	0.00154	CcSEcCtD
Betamethasone—Shock—Mitoxantrone—sarcoma	0.000453	0.00153	CcSEcCtD
Betamethasone—Pain—Dactinomycin—sarcoma	0.000453	0.00153	CcSEcCtD
Betamethasone—Anaphylactoid reaction—Epirubicin—sarcoma	0.000452	0.00152	CcSEcCtD
Betamethasone—Thrombocytopenia—Mitoxantrone—sarcoma	0.000451	0.00152	CcSEcCtD
Betamethasone—Anorexia—Vincristine—sarcoma	0.000451	0.00152	CcSEcCtD
Betamethasone—Tachycardia—Mitoxantrone—sarcoma	0.00045	0.00152	CcSEcCtD
Betamethasone—Eye pain—Doxorubicin—sarcoma	0.000448	0.00151	CcSEcCtD
Betamethasone—Cardiac failure—Epirubicin—sarcoma	0.000448	0.00151	CcSEcCtD
Betamethasone—Lethargy—Epirubicin—sarcoma	0.000446	0.0015	CcSEcCtD
Betamethasone—Cardiac failure congestive—Doxorubicin—sarcoma	0.000446	0.0015	CcSEcCtD
Betamethasone—Hyperhidrosis—Mitoxantrone—sarcoma	0.000445	0.0015	CcSEcCtD
Betamethasone—Hypotension—Vincristine—sarcoma	0.000442	0.00149	CcSEcCtD
Betamethasone—Feeling abnormal—Thiotepa—sarcoma	0.00044	0.00148	CcSEcCtD
Betamethasone—Anorexia—Mitoxantrone—sarcoma	0.000439	0.00148	CcSEcCtD
Betamethasone—Osteoarthritis—Epirubicin—sarcoma	0.000437	0.00147	CcSEcCtD
Betamethasone—Feeling abnormal—Dactinomycin—sarcoma	0.000436	0.00147	CcSEcCtD
Betamethasone—Gastrointestinal pain—Thiotepa—sarcoma	0.000436	0.00147	CcSEcCtD
Betamethasone—Ill-defined disorder—Etoposide—sarcoma	0.000436	0.00147	CcSEcCtD
Betamethasone—Gastrointestinal pain—Dactinomycin—sarcoma	0.000433	0.00146	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Vincristine—sarcoma	0.000431	0.00145	CcSEcCtD
Betamethasone—Hypotension—Mitoxantrone—sarcoma	0.000431	0.00145	CcSEcCtD
Betamethasone—Increased appetite—Doxorubicin—sarcoma	0.00043	0.00145	CcSEcCtD
Betamethasone—Affect lability—Epirubicin—sarcoma	0.00043	0.00145	CcSEcCtD
Betamethasone—Migraine—Epirubicin—sarcoma	0.00043	0.00145	CcSEcCtD
Betamethasone—Insomnia—Vincristine—sarcoma	0.000428	0.00144	CcSEcCtD
Betamethasone—PTGS2—lymph node—sarcoma	0.000426	0.0037	CbGeAlD
Betamethasone—ABCB1—bone marrow—sarcoma	0.000425	0.0037	CbGeAlD
Betamethasone—Paraesthesia—Vincristine—sarcoma	0.000425	0.00143	CcSEcCtD
Betamethasone—Urticaria—Thiotepa—sarcoma	0.000424	0.00143	CcSEcCtD
Betamethasone—Malaise—Etoposide—sarcoma	0.000423	0.00143	CcSEcCtD
Betamethasone—Dermatitis bullous—Doxorubicin—sarcoma	0.000423	0.00143	CcSEcCtD
Betamethasone—Vertigo—Etoposide—sarcoma	0.000422	0.00142	CcSEcCtD
Betamethasone—Body temperature increased—Thiotepa—sarcoma	0.000422	0.00142	CcSEcCtD
Betamethasone—Abdominal pain—Thiotepa—sarcoma	0.000422	0.00142	CcSEcCtD
Betamethasone—PTGS2—S1P1 pathway—PDGFRB—sarcoma	0.000421	0.0169	CbGpPWpGaD
Betamethasone—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.00042	0.00141	CcSEcCtD
Betamethasone—Body temperature increased—Dactinomycin—sarcoma	0.000419	0.00141	CcSEcCtD
Betamethasone—Abdominal pain—Dactinomycin—sarcoma	0.000419	0.00141	CcSEcCtD
Betamethasone—Anaphylactoid reaction—Doxorubicin—sarcoma	0.000418	0.00141	CcSEcCtD
Betamethasone—Cardiac arrest—Epirubicin—sarcoma	0.000416	0.0014	CcSEcCtD
Betamethasone—Cardiac failure—Doxorubicin—sarcoma	0.000414	0.0014	CcSEcCtD
Betamethasone—Mood swings—Epirubicin—sarcoma	0.000414	0.0014	CcSEcCtD
Betamethasone—Paraesthesia—Mitoxantrone—sarcoma	0.000414	0.00139	CcSEcCtD
Betamethasone—Loss of consciousness—Etoposide—sarcoma	0.000413	0.00139	CcSEcCtD
Betamethasone—Lethargy—Doxorubicin—sarcoma	0.000413	0.00139	CcSEcCtD
Betamethasone—Decreased appetite—Vincristine—sarcoma	0.000411	0.00139	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Vincristine—sarcoma	0.000408	0.00138	CcSEcCtD
Betamethasone—Fatigue—Vincristine—sarcoma	0.000408	0.00137	CcSEcCtD
Betamethasone—Convulsion—Etoposide—sarcoma	0.000407	0.00137	CcSEcCtD
Betamethasone—Dyspepsia—Mitoxantrone—sarcoma	0.000406	0.00137	CcSEcCtD
Betamethasone—Hypertension—Etoposide—sarcoma	0.000405	0.00137	CcSEcCtD
Betamethasone—Pain—Vincristine—sarcoma	0.000405	0.00136	CcSEcCtD
Betamethasone—Osteoarthritis—Doxorubicin—sarcoma	0.000404	0.00136	CcSEcCtD
Betamethasone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—CREB1—sarcoma	0.000403	0.0162	CbGpPWpGaD
Betamethasone—Dry skin—Epirubicin—sarcoma	0.000401	0.00135	CcSEcCtD
Betamethasone—Decreased appetite—Mitoxantrone—sarcoma	0.000401	0.00135	CcSEcCtD
Betamethasone—Migraine—Doxorubicin—sarcoma	0.000398	0.00134	CcSEcCtD
Betamethasone—Affect lability—Doxorubicin—sarcoma	0.000398	0.00134	CcSEcCtD
Betamethasone—Hypokalaemia—Epirubicin—sarcoma	0.000398	0.00134	CcSEcCtD
Betamethasone—Fatigue—Mitoxantrone—sarcoma	0.000397	0.00134	CcSEcCtD
Betamethasone—Discomfort—Etoposide—sarcoma	0.000395	0.00133	CcSEcCtD
Betamethasone—Pain—Mitoxantrone—sarcoma	0.000394	0.00133	CcSEcCtD
Betamethasone—Gastrointestinal pain—Vincristine—sarcoma	0.000387	0.0013	CcSEcCtD
Betamethasone—Muscular weakness—Epirubicin—sarcoma	0.000385	0.0013	CcSEcCtD
Betamethasone—Cardiac arrest—Doxorubicin—sarcoma	0.000385	0.0013	CcSEcCtD
Betamethasone—Anaphylactic shock—Etoposide—sarcoma	0.000383	0.00129	CcSEcCtD
Betamethasone—Mood swings—Doxorubicin—sarcoma	0.000383	0.00129	CcSEcCtD
Betamethasone—Asthenia—Thiotepa—sarcoma	0.000383	0.00129	CcSEcCtD
Betamethasone—Infection—Etoposide—sarcoma	0.000381	0.00128	CcSEcCtD
Betamethasone—Asthenia—Dactinomycin—sarcoma	0.00038	0.00128	CcSEcCtD
Betamethasone—Feeling abnormal—Mitoxantrone—sarcoma	0.00038	0.00128	CcSEcCtD
Betamethasone—Pruritus—Thiotepa—sarcoma	0.000377	0.00127	CcSEcCtD
Betamethasone—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000377	0.00127	CcSEcCtD
Betamethasone—Thrombocytopenia—Etoposide—sarcoma	0.000375	0.00126	CcSEcCtD
Betamethasone—Tachycardia—Etoposide—sarcoma	0.000374	0.00126	CcSEcCtD
Betamethasone—Body temperature increased—Vincristine—sarcoma	0.000374	0.00126	CcSEcCtD
Betamethasone—Abdominal pain—Vincristine—sarcoma	0.000374	0.00126	CcSEcCtD
Betamethasone—Dry skin—Doxorubicin—sarcoma	0.000371	0.00125	CcSEcCtD
Betamethasone—Hyperhidrosis—Etoposide—sarcoma	0.00037	0.00125	CcSEcCtD
Betamethasone—Hypokalaemia—Doxorubicin—sarcoma	0.000368	0.00124	CcSEcCtD
Betamethasone—Urticaria—Mitoxantrone—sarcoma	0.000366	0.00123	CcSEcCtD
Betamethasone—Anorexia—Etoposide—sarcoma	0.000365	0.00123	CcSEcCtD
Betamethasone—Diarrhoea—Thiotepa—sarcoma	0.000365	0.00123	CcSEcCtD
Betamethasone—Body temperature increased—Mitoxantrone—sarcoma	0.000364	0.00123	CcSEcCtD
Betamethasone—Abdominal pain—Mitoxantrone—sarcoma	0.000364	0.00123	CcSEcCtD
Betamethasone—ABCB1—testis—sarcoma	0.000363	0.00316	CbGeAlD
Betamethasone—Diarrhoea—Dactinomycin—sarcoma	0.000362	0.00122	CcSEcCtD
Betamethasone—NR3C1—Transcription factor regulation in adipogenesis—CREB1—sarcoma	0.000359	0.0144	CbGpPWpGaD
Betamethasone—Hypotension—Etoposide—sarcoma	0.000358	0.00121	CcSEcCtD
Betamethasone—Muscular weakness—Doxorubicin—sarcoma	0.000357	0.0012	CcSEcCtD
Betamethasone—PLA2G1B—Fc-epsilon receptor I signaling in mast cells—JUN—sarcoma	0.000354	0.0143	CbGpPWpGaD
Betamethasone—Dizziness—Thiotepa—sarcoma	0.000353	0.00119	CcSEcCtD
Betamethasone—PTGS2—S1P1 pathway—KDR—sarcoma	0.000349	0.014	CbGpPWpGaD
Betamethasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYOD1—sarcoma	0.000347	0.014	CbGpPWpGaD
Betamethasone—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—sarcoma	0.000346	0.0139	CbGpPWpGaD
Betamethasone—CYP19A1—FSH signaling pathway—CREB1—sarcoma	0.000345	0.0139	CbGpPWpGaD
Betamethasone—Paraesthesia—Etoposide—sarcoma	0.000344	0.00116	CcSEcCtD
Betamethasone—Weight increased—Epirubicin—sarcoma	0.000344	0.00116	CcSEcCtD
Betamethasone—ABCB1—liver—sarcoma	0.000343	0.00299	CbGeAlD
Betamethasone—Weight decreased—Epirubicin—sarcoma	0.000342	0.00115	CcSEcCtD
Betamethasone—Hyperglycaemia—Epirubicin—sarcoma	0.000341	0.00115	CcSEcCtD
Betamethasone—Asthenia—Vincristine—sarcoma	0.000339	0.00114	CcSEcCtD
Betamethasone—Vomiting—Thiotepa—sarcoma	0.000339	0.00114	CcSEcCtD
Betamethasone—Vomiting—Dactinomycin—sarcoma	0.000337	0.00113	CcSEcCtD
Betamethasone—Rash—Thiotepa—sarcoma	0.000336	0.00113	CcSEcCtD
Betamethasone—Dermatitis—Thiotepa—sarcoma	0.000336	0.00113	CcSEcCtD
Betamethasone—Headache—Thiotepa—sarcoma	0.000334	0.00113	CcSEcCtD
Betamethasone—Rash—Dactinomycin—sarcoma	0.000334	0.00113	CcSEcCtD
Betamethasone—Decreased appetite—Etoposide—sarcoma	0.000333	0.00112	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Etoposide—sarcoma	0.000331	0.00112	CcSEcCtD
Betamethasone—Asthenia—Mitoxantrone—sarcoma	0.000331	0.00111	CcSEcCtD
Betamethasone—Fatigue—Etoposide—sarcoma	0.00033	0.00111	CcSEcCtD
Betamethasone—Neuropathy peripheral—Epirubicin—sarcoma	0.00033	0.00111	CcSEcCtD
Betamethasone—Pain—Etoposide—sarcoma	0.000328	0.0011	CcSEcCtD
Betamethasone—Conjunctivitis—Epirubicin—sarcoma	0.000327	0.0011	CcSEcCtD
Betamethasone—Diarrhoea—Vincristine—sarcoma	0.000324	0.00109	CcSEcCtD
Betamethasone—Weight increased—Doxorubicin—sarcoma	0.000318	0.00107	CcSEcCtD
Betamethasone—Nausea—Thiotepa—sarcoma	0.000317	0.00107	CcSEcCtD
Betamethasone—Weight decreased—Doxorubicin—sarcoma	0.000316	0.00107	CcSEcCtD
Betamethasone—Feeling abnormal—Etoposide—sarcoma	0.000316	0.00106	CcSEcCtD
Betamethasone—Hyperglycaemia—Doxorubicin—sarcoma	0.000315	0.00106	CcSEcCtD
Betamethasone—Diarrhoea—Mitoxantrone—sarcoma	0.000315	0.00106	CcSEcCtD
Betamethasone—Nausea—Dactinomycin—sarcoma	0.000315	0.00106	CcSEcCtD
Betamethasone—Gastrointestinal pain—Etoposide—sarcoma	0.000313	0.00106	CcSEcCtD
Betamethasone—Dizziness—Vincristine—sarcoma	0.000313	0.00105	CcSEcCtD
Betamethasone—Bradycardia—Epirubicin—sarcoma	0.000308	0.00104	CcSEcCtD
Betamethasone—Neuropathy peripheral—Doxorubicin—sarcoma	0.000305	0.00103	CcSEcCtD
Betamethasone—Urticaria—Etoposide—sarcoma	0.000304	0.00103	CcSEcCtD
Betamethasone—Haemoglobin—Epirubicin—sarcoma	0.000304	0.00102	CcSEcCtD
Betamethasone—Abdominal pain—Etoposide—sarcoma	0.000303	0.00102	CcSEcCtD
Betamethasone—Body temperature increased—Etoposide—sarcoma	0.000303	0.00102	CcSEcCtD
Betamethasone—Conjunctivitis—Doxorubicin—sarcoma	0.000303	0.00102	CcSEcCtD
Betamethasone—Haemorrhage—Epirubicin—sarcoma	0.000302	0.00102	CcSEcCtD
Betamethasone—Vomiting—Vincristine—sarcoma	0.000301	0.00101	CcSEcCtD
Betamethasone—Rash—Vincristine—sarcoma	0.000298	0.00101	CcSEcCtD
Betamethasone—Dermatitis—Vincristine—sarcoma	0.000298	0.001	CcSEcCtD
Betamethasone—Headache—Vincristine—sarcoma	0.000296	0.000999	CcSEcCtD
Betamethasone—Vomiting—Mitoxantrone—sarcoma	0.000293	0.000987	CcSEcCtD
Betamethasone—Visual impairment—Epirubicin—sarcoma	0.000291	0.000982	CcSEcCtD
Betamethasone—Rash—Mitoxantrone—sarcoma	0.00029	0.000979	CcSEcCtD
Betamethasone—Dermatitis—Mitoxantrone—sarcoma	0.00029	0.000978	CcSEcCtD
Betamethasone—Headache—Mitoxantrone—sarcoma	0.000289	0.000973	CcSEcCtD
Betamethasone—Bradycardia—Doxorubicin—sarcoma	0.000285	0.00096	CcSEcCtD
Betamethasone—Eye disorder—Epirubicin—sarcoma	0.000283	0.000952	CcSEcCtD
Betamethasone—Haemoglobin—Doxorubicin—sarcoma	0.000281	0.000948	CcSEcCtD
Betamethasone—Nausea—Vincristine—sarcoma	0.000281	0.000947	CcSEcCtD
Betamethasone—Haemorrhage—Doxorubicin—sarcoma	0.00028	0.000943	CcSEcCtD
Betamethasone—Asthenia—Etoposide—sarcoma	0.000275	0.000927	CcSEcCtD
Betamethasone—Angiopathy—Epirubicin—sarcoma	0.000274	0.000925	CcSEcCtD
Betamethasone—Nausea—Mitoxantrone—sarcoma	0.000274	0.000922	CcSEcCtD
Betamethasone—Pruritus—Etoposide—sarcoma	0.000271	0.000914	CcSEcCtD
Betamethasone—Arrhythmia—Epirubicin—sarcoma	0.00027	0.00091	CcSEcCtD
Betamethasone—Visual impairment—Doxorubicin—sarcoma	0.00027	0.000909	CcSEcCtD
Betamethasone—Alopecia—Epirubicin—sarcoma	0.000267	0.000901	CcSEcCtD
Betamethasone—ABCB1—lymph node—sarcoma	0.000263	0.00229	CbGeAlD
Betamethasone—Erythema—Epirubicin—sarcoma	0.000263	0.000887	CcSEcCtD
Betamethasone—Diarrhoea—Etoposide—sarcoma	0.000262	0.000884	CcSEcCtD
Betamethasone—Eye disorder—Doxorubicin—sarcoma	0.000261	0.000881	CcSEcCtD
Betamethasone—PTGS2—C-MYB transcription factor network—CD34—sarcoma	0.000256	0.0103	CbGpPWpGaD
Betamethasone—PTGS2—C-MYB transcription factor network—MYOD1—sarcoma	0.000256	0.0103	CbGpPWpGaD
Betamethasone—Angiopathy—Doxorubicin—sarcoma	0.000254	0.000856	CcSEcCtD
Betamethasone—Dizziness—Etoposide—sarcoma	0.000253	0.000854	CcSEcCtD
Betamethasone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—sarcoma	0.000252	0.0102	CbGpPWpGaD
Betamethasone—Arrhythmia—Doxorubicin—sarcoma	0.00025	0.000842	CcSEcCtD
Betamethasone—Alopecia—Doxorubicin—sarcoma	0.000247	0.000833	CcSEcCtD
Betamethasone—NR3C1—Regulation of Androgen receptor activity—FOXO1—sarcoma	0.000245	0.00985	CbGpPWpGaD
Betamethasone—Ill-defined disorder—Epirubicin—sarcoma	0.000244	0.000823	CcSEcCtD
Betamethasone—Vomiting—Etoposide—sarcoma	0.000244	0.000821	CcSEcCtD
Betamethasone—Erythema—Doxorubicin—sarcoma	0.000244	0.000821	CcSEcCtD
Betamethasone—Rash—Etoposide—sarcoma	0.000242	0.000814	CcSEcCtD
Betamethasone—Dermatitis—Etoposide—sarcoma	0.000241	0.000814	CcSEcCtD
Betamethasone—Headache—Etoposide—sarcoma	0.00024	0.000809	CcSEcCtD
Betamethasone—Malaise—Epirubicin—sarcoma	0.000237	0.0008	CcSEcCtD
Betamethasone—Vertigo—Epirubicin—sarcoma	0.000236	0.000797	CcSEcCtD
Betamethasone—Syncope—Epirubicin—sarcoma	0.000236	0.000796	CcSEcCtD
Betamethasone—Loss of consciousness—Epirubicin—sarcoma	0.000231	0.00078	CcSEcCtD
Betamethasone—Convulsion—Epirubicin—sarcoma	0.000228	0.000769	CcSEcCtD
Betamethasone—Nausea—Etoposide—sarcoma	0.000228	0.000767	CcSEcCtD
Betamethasone—Hypertension—Epirubicin—sarcoma	0.000227	0.000766	CcSEcCtD
Betamethasone—Ill-defined disorder—Doxorubicin—sarcoma	0.000226	0.000762	CcSEcCtD
Betamethasone—Myalgia—Epirubicin—sarcoma	0.000224	0.000755	CcSEcCtD
Betamethasone—PLA2G1B—Fc-epsilon receptor I signaling in mast cells—HRAS—sarcoma	0.000224	0.009	CbGpPWpGaD
Betamethasone—Anxiety—Epirubicin—sarcoma	0.000223	0.000753	CcSEcCtD
Betamethasone—CYP19A1—FSH signaling pathway—SRC—sarcoma	0.000223	0.00897	CbGpPWpGaD
Betamethasone—Discomfort—Epirubicin—sarcoma	0.000221	0.000746	CcSEcCtD
Betamethasone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—sarcoma	0.00022	0.00887	CbGpPWpGaD
Betamethasone—Malaise—Doxorubicin—sarcoma	0.00022	0.00074	CcSEcCtD
Betamethasone—Vertigo—Doxorubicin—sarcoma	0.000219	0.000738	CcSEcCtD
Betamethasone—Syncope—Doxorubicin—sarcoma	0.000218	0.000736	CcSEcCtD
Betamethasone—Oedema—Epirubicin—sarcoma	0.000215	0.000724	CcSEcCtD
Betamethasone—Anaphylactic shock—Epirubicin—sarcoma	0.000215	0.000724	CcSEcCtD
Betamethasone—Loss of consciousness—Doxorubicin—sarcoma	0.000214	0.000722	CcSEcCtD
Betamethasone—Infection—Epirubicin—sarcoma	0.000213	0.000719	CcSEcCtD
Betamethasone—ABCB1—HIF-1-alpha transcription factor network—NPM1—sarcoma	0.000212	0.00852	CbGpPWpGaD
Betamethasone—Shock—Epirubicin—sarcoma	0.000211	0.000712	CcSEcCtD
Betamethasone—Convulsion—Doxorubicin—sarcoma	0.000211	0.000711	CcSEcCtD
Betamethasone—Nervous system disorder—Epirubicin—sarcoma	0.000211	0.00071	CcSEcCtD
Betamethasone—Thrombocytopenia—Epirubicin—sarcoma	0.00021	0.000709	CcSEcCtD
Betamethasone—Hypertension—Doxorubicin—sarcoma	0.00021	0.000709	CcSEcCtD
Betamethasone—Tachycardia—Epirubicin—sarcoma	0.00021	0.000707	CcSEcCtD
Betamethasone—Hyperhidrosis—Epirubicin—sarcoma	0.000208	0.0007	CcSEcCtD
Betamethasone—Myalgia—Doxorubicin—sarcoma	0.000207	0.000699	CcSEcCtD
Betamethasone—Anxiety—Doxorubicin—sarcoma	0.000207	0.000696	CcSEcCtD
Betamethasone—NR3C1—FOXA2 and FOXA3 transcription factor networks—CREB1—sarcoma	0.000206	0.00829	CbGpPWpGaD
Betamethasone—Discomfort—Doxorubicin—sarcoma	0.000205	0.000691	CcSEcCtD
Betamethasone—Anorexia—Epirubicin—sarcoma	0.000205	0.00069	CcSEcCtD
Betamethasone—PTGS2—Selenium Micronutrient Network—HBA1—sarcoma	0.000204	0.00821	CbGpPWpGaD
Betamethasone—Hypotension—Epirubicin—sarcoma	0.000201	0.000677	CcSEcCtD
Betamethasone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	0.000201	0.00808	CbGpPWpGaD
Betamethasone—Oedema—Doxorubicin—sarcoma	0.000199	0.00067	CcSEcCtD
Betamethasone—Anaphylactic shock—Doxorubicin—sarcoma	0.000199	0.00067	CcSEcCtD
Betamethasone—Infection—Doxorubicin—sarcoma	0.000197	0.000666	CcSEcCtD
Betamethasone—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000197	0.00793	CbGpPWpGaD
Betamethasone—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000196	0.00066	CcSEcCtD
Betamethasone—Shock—Doxorubicin—sarcoma	0.000196	0.000659	CcSEcCtD
Betamethasone—Nervous system disorder—Doxorubicin—sarcoma	0.000195	0.000657	CcSEcCtD
Betamethasone—Thrombocytopenia—Doxorubicin—sarcoma	0.000195	0.000656	CcSEcCtD
Betamethasone—Insomnia—Epirubicin—sarcoma	0.000194	0.000655	CcSEcCtD
Betamethasone—Tachycardia—Doxorubicin—sarcoma	0.000194	0.000654	CcSEcCtD
Betamethasone—Paraesthesia—Epirubicin—sarcoma	0.000193	0.00065	CcSEcCtD
Betamethasone—NR3C2—Gene Expression—FUS—sarcoma	0.000192	0.00774	CbGpPWpGaD
Betamethasone—Hyperhidrosis—Doxorubicin—sarcoma	0.000192	0.000648	CcSEcCtD
Betamethasone—PTGS2—S1P1 pathway—VEGFA—sarcoma	0.000192	0.00773	CbGpPWpGaD
Betamethasone—PGR—Validated nuclear estrogen receptor alpha network—CCND1—sarcoma	0.00019	0.00766	CbGpPWpGaD
Betamethasone—PGR—Validated nuclear estrogen receptor alpha network—JUN—sarcoma	0.00019	0.00765	CbGpPWpGaD
Betamethasone—Anorexia—Doxorubicin—sarcoma	0.000189	0.000639	CcSEcCtD
Betamethasone—Dyspepsia—Epirubicin—sarcoma	0.000189	0.000637	CcSEcCtD
Betamethasone—PTGS2—Signaling mediated by p38-alpha and p38-beta—CREB1—sarcoma	0.000187	0.00755	CbGpPWpGaD
Betamethasone—Decreased appetite—Epirubicin—sarcoma	0.000187	0.000629	CcSEcCtD
Betamethasone—CYP19A1—Tryptophan metabolism—MDM2—sarcoma	0.000187	0.00751	CbGpPWpGaD
Betamethasone—Hypotension—Doxorubicin—sarcoma	0.000186	0.000626	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Epirubicin—sarcoma	0.000185	0.000625	CcSEcCtD
Betamethasone—Fatigue—Epirubicin—sarcoma	0.000185	0.000624	CcSEcCtD
Betamethasone—Pain—Epirubicin—sarcoma	0.000184	0.000619	CcSEcCtD
Betamethasone—PGR—Signaling by ERBB4—FOXO1—sarcoma	0.000182	0.00734	CbGpPWpGaD
Betamethasone—PGR—Signaling by ERBB4—PDGFRB—sarcoma	0.000182	0.00732	CbGpPWpGaD
Betamethasone—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000181	0.00061	CcSEcCtD
Betamethasone—Insomnia—Doxorubicin—sarcoma	0.00018	0.000606	CcSEcCtD
Betamethasone—PGR—Signaling by ERBB4—PDGFRA—sarcoma	0.000179	0.00721	CbGpPWpGaD
Betamethasone—Paraesthesia—Doxorubicin—sarcoma	0.000178	0.000602	CcSEcCtD
Betamethasone—Feeling abnormal—Epirubicin—sarcoma	0.000177	0.000597	CcSEcCtD
Betamethasone—Gastrointestinal pain—Epirubicin—sarcoma	0.000176	0.000592	CcSEcCtD
Betamethasone—Dyspepsia—Doxorubicin—sarcoma	0.000175	0.00059	CcSEcCtD
Betamethasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—FOXO1—sarcoma	0.000174	0.00702	CbGpPWpGaD
Betamethasone—Decreased appetite—Doxorubicin—sarcoma	0.000173	0.000582	CcSEcCtD
Betamethasone—NR3C1—Circadian Clock—CREB1—sarcoma	0.000172	0.00694	CbGpPWpGaD
Betamethasone—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000172	0.000578	CcSEcCtD
Betamethasone—Fatigue—Doxorubicin—sarcoma	0.000171	0.000578	CcSEcCtD
Betamethasone—Urticaria—Epirubicin—sarcoma	0.000171	0.000575	CcSEcCtD
Betamethasone—Pain—Doxorubicin—sarcoma	0.00017	0.000573	CcSEcCtD
Betamethasone—Abdominal pain—Epirubicin—sarcoma	0.00017	0.000572	CcSEcCtD
Betamethasone—Body temperature increased—Epirubicin—sarcoma	0.00017	0.000572	CcSEcCtD
Betamethasone—Feeling abnormal—Doxorubicin—sarcoma	0.000164	0.000552	CcSEcCtD
Betamethasone—Gastrointestinal pain—Doxorubicin—sarcoma	0.000163	0.000548	CcSEcCtD
Betamethasone—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—sarcoma	0.000161	0.00649	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—ATF1—sarcoma	0.000161	0.00647	CbGpPWpGaD
Betamethasone—Urticaria—Doxorubicin—sarcoma	0.000158	0.000532	CcSEcCtD
Betamethasone—Body temperature increased—Doxorubicin—sarcoma	0.000157	0.00053	CcSEcCtD
Betamethasone—Abdominal pain—Doxorubicin—sarcoma	0.000157	0.00053	CcSEcCtD
Betamethasone—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—sarcoma	0.000157	0.00631	CbGpPWpGaD
Betamethasone—Asthenia—Epirubicin—sarcoma	0.000154	0.00052	CcSEcCtD
Betamethasone—PGR—Validated nuclear estrogen receptor alpha network—MYC—sarcoma	0.000153	0.00615	CbGpPWpGaD
Betamethasone—Pruritus—Epirubicin—sarcoma	0.000152	0.000512	CcSEcCtD
Betamethasone—ABCB1—HIF-1-alpha transcription factor network—CXCR4—sarcoma	0.000149	0.00601	CbGpPWpGaD
Betamethasone—Diarrhoea—Epirubicin—sarcoma	0.000147	0.000495	CcSEcCtD
Betamethasone—NR3C1—Regulation of Androgen receptor activity—MDM2—sarcoma	0.000147	0.00591	CbGpPWpGaD
Betamethasone—Asthenia—Doxorubicin—sarcoma	0.000143	0.000481	CcSEcCtD
Betamethasone—NR3C1—AP-1 transcription factor network—CREB1—sarcoma	0.000142	0.00572	CbGpPWpGaD
Betamethasone—Dizziness—Epirubicin—sarcoma	0.000142	0.000479	CcSEcCtD
Betamethasone—Pruritus—Doxorubicin—sarcoma	0.000141	0.000474	CcSEcCtD
Betamethasone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	0.00014	0.00563	CbGpPWpGaD
Betamethasone—PGR—Signaling by ERBB4—KIT—sarcoma	0.000139	0.00559	CbGpPWpGaD
Betamethasone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	0.000138	0.00554	CbGpPWpGaD
Betamethasone—Vomiting—Epirubicin—sarcoma	0.000137	0.00046	CcSEcCtD
Betamethasone—Diarrhoea—Doxorubicin—sarcoma	0.000136	0.000458	CcSEcCtD
Betamethasone—Rash—Epirubicin—sarcoma	0.000135	0.000457	CcSEcCtD
Betamethasone—Dermatitis—Epirubicin—sarcoma	0.000135	0.000456	CcSEcCtD
Betamethasone—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—sarcoma	0.000135	0.00543	CbGpPWpGaD
Betamethasone—Headache—Epirubicin—sarcoma	0.000135	0.000454	CcSEcCtD
Betamethasone—PGR—Signaling by ERBB4—CREB1—sarcoma	0.000132	0.00532	CbGpPWpGaD
Betamethasone—Dizziness—Doxorubicin—sarcoma	0.000131	0.000443	CcSEcCtD
Betamethasone—NR3C1—Regulation of Androgen receptor activity—JUN—sarcoma	0.000128	0.00514	CbGpPWpGaD
Betamethasone—Nausea—Epirubicin—sarcoma	0.000128	0.00043	CcSEcCtD
Betamethasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREB1—sarcoma	0.000126	0.00509	CbGpPWpGaD
Betamethasone—Vomiting—Doxorubicin—sarcoma	0.000126	0.000426	CcSEcCtD
Betamethasone—Rash—Doxorubicin—sarcoma	0.000125	0.000422	CcSEcCtD
Betamethasone—Dermatitis—Doxorubicin—sarcoma	0.000125	0.000422	CcSEcCtD
Betamethasone—NR3C1—Glucocorticoid receptor regulatory network—CREB1—sarcoma	0.000125	0.00504	CbGpPWpGaD
Betamethasone—Headache—Doxorubicin—sarcoma	0.000125	0.00042	CcSEcCtD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000123	0.00496	CbGpPWpGaD
Betamethasone—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000121	0.00488	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—FOXO1—sarcoma	0.00012	0.00484	CbGpPWpGaD
Betamethasone—NR3C1—Adipogenesis—FOXO1—sarcoma	0.000119	0.00481	CbGpPWpGaD
Betamethasone—Nausea—Doxorubicin—sarcoma	0.000118	0.000398	CcSEcCtD
Betamethasone—PGR—Gene Expression—FUS—sarcoma	0.000117	0.00471	CbGpPWpGaD
Betamethasone—NR3C1—Regulation of Androgen receptor activity—SRC—sarcoma	0.000114	0.00461	CbGpPWpGaD
Betamethasone—PGR—Signaling by ERBB4—MDM2—sarcoma	0.000109	0.0044	CbGpPWpGaD
Betamethasone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	0.000107	0.00429	CbGpPWpGaD
Betamethasone—NR3C1—AP-1 transcription factor network—IL2—sarcoma	0.000105	0.00423	CbGpPWpGaD
Betamethasone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—sarcoma	0.000104	0.00419	CbGpPWpGaD
Betamethasone—NR3C1—Endoderm Differentiation—CTNNB1—sarcoma	0.000104	0.00418	CbGpPWpGaD
Betamethasone—NR3C1—Glucocorticoid receptor regulatory network—MDM2—sarcoma	0.000104	0.00417	CbGpPWpGaD
Betamethasone—NR3C1—AP-1 transcription factor network—CCND1—sarcoma	0.000102	0.00412	CbGpPWpGaD
Betamethasone—NR3C1—AP-1 transcription factor network—JUN—sarcoma	0.000102	0.00411	CbGpPWpGaD
Betamethasone—NR3C1—AP-1 transcription factor network—CTNNB1—sarcoma	0.000101	0.00408	CbGpPWpGaD
Betamethasone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—sarcoma	0.000101	0.00408	CbGpPWpGaD
Betamethasone—PTGS2—C-MYB transcription factor network—KIT—sarcoma	9.78e-05	0.00394	CbGpPWpGaD
Betamethasone—PTGS2—Aryl Hydrocarbon Receptor—SRC—sarcoma	9.72e-05	0.00391	CbGpPWpGaD
Betamethasone—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	9.47e-05	0.00381	CbGpPWpGaD
Betamethasone—ABCB1—Allograft Rejection—PDGFRA—sarcoma	9.39e-05	0.00378	CbGpPWpGaD
Betamethasone—PTGS2—Aryl Hydrocarbon Receptor—NRAS—sarcoma	9.35e-05	0.00376	CbGpPWpGaD
Betamethasone—NR3C1—Glucocorticoid receptor regulatory network—IL2—sarcoma	9.25e-05	0.00373	CbGpPWpGaD
Betamethasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—sarcoma	9.09e-05	0.00366	CbGpPWpGaD
Betamethasone—NR3C1—Glucocorticoid receptor regulatory network—JUN—sarcoma	9e-05	0.00362	CbGpPWpGaD
Betamethasone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—sarcoma	8.9e-05	0.00358	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	8.73e-05	0.00351	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—CREB1—sarcoma	8.71e-05	0.00351	CbGpPWpGaD
Betamethasone—PTGS2—Aryl Hydrocarbon Receptor—MYC—sarcoma	8.71e-05	0.00351	CbGpPWpGaD
Betamethasone—NR3C1—Adipogenesis—CREB1—sarcoma	8.66e-05	0.00349	CbGpPWpGaD
Betamethasone—PTGS2—Aryl Hydrocarbon Receptor—EGFR—sarcoma	8.52e-05	0.00343	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—ENO2—sarcoma	8.42e-05	0.00339	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—HBA1—sarcoma	8.37e-05	0.00337	CbGpPWpGaD
Betamethasone—NR3C1—AP-1 transcription factor network—MYC—sarcoma	8.21e-05	0.00331	CbGpPWpGaD
Betamethasone—PGR—Signaling by ERBB4—NRAS—sarcoma	8.2e-05	0.0033	CbGpPWpGaD
Betamethasone—PTGS2—Aryl Hydrocarbon Receptor—KRAS—sarcoma	8.05e-05	0.00324	CbGpPWpGaD
Betamethasone—ABCB1—HIF-1-alpha transcription factor network—CREB1—sarcoma	8e-05	0.00322	CbGpPWpGaD
Betamethasone—NR3C1—SIDS Susceptibility Pathways—CREB1—sarcoma	7.48e-05	0.00301	CbGpPWpGaD
Betamethasone—PGR—Signaling by ERBB4—EGFR—sarcoma	7.47e-05	0.00301	CbGpPWpGaD
Betamethasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—sarcoma	7.31e-05	0.00294	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—MDM2—sarcoma	7.21e-05	0.0029	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—PLCG1—sarcoma	7.14e-05	0.00288	CbGpPWpGaD
Betamethasone—PGR—Signaling by ERBB4—KRAS—sarcoma	7.06e-05	0.00284	CbGpPWpGaD
Betamethasone—PTGS2—Aryl Hydrocarbon Receptor—HRAS—sarcoma	6.84e-05	0.00275	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—FUS—sarcoma	6.77e-05	0.00272	CbGpPWpGaD
Betamethasone—NR3C1—AP-1 transcription factor network—TP53—sarcoma	6.74e-05	0.00272	CbGpPWpGaD
Betamethasone—PTGS2—C-MYB transcription factor network—CCND1—sarcoma	6.71e-05	0.0027	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	6.54e-05	0.00263	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—CCND1—sarcoma	6.28e-05	0.00253	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—JUN—sarcoma	6.27e-05	0.00252	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—CTNNB1—sarcoma	6.22e-05	0.0025	CbGpPWpGaD
Betamethasone—NR3C1—Adipogenesis—CTNNB1—sarcoma	6.18e-05	0.00249	CbGpPWpGaD
Betamethasone—PGR—Signaling by ERBB4—HRAS—sarcoma	6e-05	0.00242	CbGpPWpGaD
Betamethasone—NR3C1—Glucocorticoid receptor regulatory network—TP53—sarcoma	5.94e-05	0.00239	CbGpPWpGaD
Betamethasone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	5.87e-05	0.00236	CbGpPWpGaD
Betamethasone—PTGS2—C-MYB transcription factor network—NRAS—sarcoma	5.78e-05	0.00233	CbGpPWpGaD
Betamethasone—ABCB1—HIF-1-alpha transcription factor network—JUN—sarcoma	5.75e-05	0.00232	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—sarcoma	5.47e-05	0.0022	CbGpPWpGaD
Betamethasone—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	5.44e-05	0.00219	CbGpPWpGaD
Betamethasone—NR3C1—SIDS Susceptibility Pathways—JUN—sarcoma	5.38e-05	0.00217	CbGpPWpGaD
Betamethasone—PTGS2—C-MYB transcription factor network—MYC—sarcoma	5.38e-05	0.00217	CbGpPWpGaD
Betamethasone—NR3C1—SIDS Susceptibility Pathways—CTNNB1—sarcoma	5.34e-05	0.00215	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—IL2—sarcoma	5.24e-05	0.00211	CbGpPWpGaD
Betamethasone—NR3C2—Generic Transcription Pathway—MYC—sarcoma	5.19e-05	0.00209	CbGpPWpGaD
Betamethasone—ABCB1—Allograft Rejection—IL2—sarcoma	5.12e-05	0.00206	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—CCND1—sarcoma	5.11e-05	0.00206	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—MYC—sarcoma	5.04e-05	0.00203	CbGpPWpGaD
Betamethasone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—sarcoma	5.03e-05	0.00202	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—TLE1—sarcoma	5.02e-05	0.00202	CbGpPWpGaD
Betamethasone—PTGS2—C-MYB transcription factor network—KRAS—sarcoma	4.97e-05	0.002	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—EGFR—sarcoma	4.93e-05	0.00198	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	4.82e-05	0.00194	CbGpPWpGaD
Betamethasone—NR3C1—SIDS Susceptibility Pathways—VEGFA—sarcoma	4.7e-05	0.00189	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—KRAS—sarcoma	4.65e-05	0.00187	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	4.63e-05	0.00187	CbGpPWpGaD
Betamethasone—ABCB1—Allograft Rejection—VEGFA—sarcoma	4.35e-05	0.00175	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—VEGFC—sarcoma	4.23e-05	0.0017	CbGpPWpGaD
Betamethasone—PTGS2—C-MYB transcription factor network—HRAS—sarcoma	4.23e-05	0.0017	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—TP53—sarcoma	4.14e-05	0.00167	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—MYC—sarcoma	4.1e-05	0.00165	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—EGFR—sarcoma	4.01e-05	0.00161	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	3.99e-05	0.00161	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	3.48e-05	0.0014	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	3.47e-05	0.0014	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	3.44e-05	0.00139	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	3.42e-05	0.00138	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—FLT1—sarcoma	3.38e-05	0.00136	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—TP53—sarcoma	3.37e-05	0.00136	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—PLCG1—sarcoma	3.33e-05	0.00134	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—CXCR4—sarcoma	3.2e-05	0.00129	CbGpPWpGaD
Betamethasone—PGR—Generic Transcription Pathway—MYC—sarcoma	3.16e-05	0.00127	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—ATF1—sarcoma	3.16e-05	0.00127	CbGpPWpGaD
Betamethasone—PTGS2—Disease—TLE1—sarcoma	3.14e-05	0.00126	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	3.11e-05	0.00125	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—ENO2—sarcoma	3.07e-05	0.00124	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—HBA1—sarcoma	3.06e-05	0.00123	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	3.03e-05	0.00122	CbGpPWpGaD
Betamethasone—PTGS2—Disease—NPM1—sarcoma	2.83e-05	0.00114	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	2.83e-05	0.00114	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	2.79e-05	0.00112	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	2.73e-05	0.0011	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—PLCG1—sarcoma	2.61e-05	0.00105	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	2.58e-05	0.00104	CbGpPWpGaD
Betamethasone—NR3C2—Gene Expression—MYC—sarcoma	2.5e-05	0.00101	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—IGF1R—sarcoma	2.48e-05	0.000999	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	2.46e-05	0.000992	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	2.46e-05	0.00099	CbGpPWpGaD
Betamethasone—PTGS2—Disease—ENO2—sarcoma	2.45e-05	0.000988	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	2.44e-05	0.000982	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—FOXO1—sarcoma	2.36e-05	0.00095	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—PDGFRB—sarcoma	2.36e-05	0.000949	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—PDGFRA—sarcoma	2.32e-05	0.000934	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	2.29e-05	0.000922	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	2.21e-05	0.000888	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	2.15e-05	0.000865	CbGpPWpGaD
Betamethasone—PTGS2—Disease—PLCG1—sarcoma	2.08e-05	0.000838	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—ENO2—sarcoma	2.05e-05	0.000827	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—HBA1—sarcoma	2.04e-05	0.000822	CbGpPWpGaD
Betamethasone—PTGS2—Disease—CXCR4—sarcoma	2e-05	0.000805	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	1.98e-05	0.000796	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—KDR—sarcoma	1.95e-05	0.000786	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	1.93e-05	0.000778	CbGpPWpGaD
Betamethasone—NR3C1—Generic Transcription Pathway—MYC—sarcoma	1.83e-05	0.000736	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	1.83e-05	0.000735	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—KIT—sarcoma	1.8e-05	0.000724	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—PLCG1—sarcoma	1.74e-05	0.000702	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—CREB1—sarcoma	1.71e-05	0.000689	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	1.62e-05	0.000654	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—MYC—sarcoma	1.52e-05	0.000613	CbGpPWpGaD
Betamethasone—PTGS2—Disease—FOXO1—sarcoma	1.48e-05	0.000595	CbGpPWpGaD
Betamethasone—PTGS2—Disease—PDGFRB—sarcoma	1.47e-05	0.000594	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—ENO2—sarcoma	1.46e-05	0.000586	CbGpPWpGaD
Betamethasone—PTGS2—Disease—PDGFRA—sarcoma	1.45e-05	0.000584	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—HBA1—sarcoma	1.45e-05	0.000583	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—MDM2—sarcoma	1.42e-05	0.00057	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—IL2—sarcoma	1.27e-05	0.00051	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PLCG1—sarcoma	1.24e-05	0.000497	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—CCND1—sarcoma	1.23e-05	0.000497	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—JUN—sarcoma	1.23e-05	0.000496	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—CTNNB1—sarcoma	1.22e-05	0.000492	CbGpPWpGaD
Betamethasone—PTGS2—Disease—KIT—sarcoma	1.13e-05	0.000453	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—SRC—sarcoma	1.1e-05	0.000445	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—VEGFA—sarcoma	1.08e-05	0.000433	CbGpPWpGaD
Betamethasone—PTGS2—Disease—CREB1—sarcoma	1.07e-05	0.000431	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—NRAS—sarcoma	1.06e-05	0.000428	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—MYC—sarcoma	9.9e-06	0.000398	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—EGFR—sarcoma	9.68e-06	0.00039	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—KRAS—sarcoma	9.15e-06	0.000368	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—ENO2—sarcoma	8.97e-06	0.000361	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—HBA1—sarcoma	8.92e-06	0.000359	CbGpPWpGaD
Betamethasone—PTGS2—Disease—MDM2—sarcoma	8.86e-06	0.000357	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—MYC—sarcoma	8.8e-06	0.000354	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—TP53—sarcoma	8.13e-06	0.000327	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—HRAS—sarcoma	7.77e-06	0.000313	CbGpPWpGaD
Betamethasone—PTGS2—Disease—CTNNB1—sarcoma	7.64e-06	0.000308	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PLCG1—sarcoma	7.61e-06	0.000306	CbGpPWpGaD
Betamethasone—PTGS2—Disease—SRC—sarcoma	6.91e-06	0.000278	CbGpPWpGaD
Betamethasone—PTGS2—Disease—NRAS—sarcoma	6.65e-06	0.000268	CbGpPWpGaD
Betamethasone—PTGS2—Disease—MYC—sarcoma	6.19e-06	0.000249	CbGpPWpGaD
Betamethasone—PTGS2—Disease—EGFR—sarcoma	6.06e-06	0.000244	CbGpPWpGaD
Betamethasone—PTGS2—Disease—KRAS—sarcoma	5.72e-06	0.00023	CbGpPWpGaD
Betamethasone—PTGS2—Disease—HRAS—sarcoma	4.86e-06	0.000196	CbGpPWpGaD
